Idarubicin containing regimen in multiple myeloma: Preliminary results of a pilot study using a modified "TANDEM" transplant program

Leukemia and Lymphoma

Volumn 44, Issue 2, 2003, Pages 299-302

  Martinelli, G ^a   Agazzi, A ^a   Laszlo, D ^a   Santoro, P ^a   Mancuso, P ^a   Pruneri, G C ^a   Greco, P ^b   Bertolini, F ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Pharmacia Corporation   (Italy)

Author keywords

Idarubicin; Melphalan; Multiple myeloma; Tandem autologous transplant

Indexed keywords

ACICLOVIR; AMIKACIN; ANTHRACYCLINE; BUSULFAN; CEFTAZIDIME; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; NARCOTIC ANALGESIC AGENT; THALIDOMIDE; THIOTEPA; VINCRISTINE;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; FEVER; HEMATOLOGIC DISEASE; HUMAN; INTERSTITIAL PNEUMONIA; LEGIONELLA; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA AND VOMITING; PAIN; PILOT STUDY; PRIORITY JOURNAL; SEPSIS; STEM CELL TRANSPLANTATION; STOMATITIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; IDARUBICIN; LEGIONNAIRES' DISEASE; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 0037299478     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000029687     Document Type: Article

References (20)

1. Vesole, D.H., Simic, A. and Lazarus, H.M. (2001) "Controversy in multiple myeloma transplants: tandem autotransplants and mini-allograft", Bone Marrow Transplant. 28, 725-735.
2. Attal, M., Harousseau, J.L., Stoppa, A.M., et al. (1996) "A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Francais du Myelome", New Engl. J. Med. 335, 2568-2576.
3. Vesole, D.H., Tricot, G., Jagannath, S., et al. (1996) "Autotransplant in multiple myeloma: what have we learned?", Blood 88(3), 838-847.
4. Barlogie, B., Jagannath, S., Vesole, D.H., et al. (1997) "Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma", Blood 89, 789-793.
5. Gahrton, G., Svensson, H., Cavo, M., et al. (2001) "Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres", Br. J. Haematol. 113(1), 209-216.
6. Alegre, A., Lamana, M., Arranz, R., et al. (1995) "Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma", Br. J. Haematol. 91, 380-386.
7. Schiller, G., Nimer, S., Vescio, R., et al. (1994) "Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma", Bone Marrow Transplant. 14, 131-136.
8. Long, G.D., Chao, N.J., Hu, W.W., et al. (1996) "High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma", Cancer 78(12), 2502-2509.
9. Dimopoulos, M.A., Alexanian, R., Przepiorka, et al. (1993) "Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high risk multiple myeloma", Blood 82, 2324-2328.
10. Ballester, O.F., Moscinski, L.C., Fields, K.K., et al. (1997) "Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel induction chemotherapy regimen for patients with high-risk multiple myeloma", Br. J. Haematol. 96, 746-748.
11. Wiernik, P.H. (1992) "Cytarabin plus idarubicin or daunorubicin as induction and consolidation therapy for previous untreated adult patients with acute myeloid leukemia", Blood 79, 313-319.
12. Fields, S.M. and Koeller, J.M. (1991) "Idarubicin: a second generation antracyclin, DICP", Ann. Pharmacother. 25, 505-517.
13. Heyll, A., Sohngen, D., Kobbe, G., et al. (1997) "Idarubicin melphalan and cyclophosphamide: an intensified high dose regimen for the treatment of myeloma patients", Leukemia 11, 32-34.
14. Meloni, G., Capria, S., Trasarti, S., et al. (2000) "High-dose idarubicin, busulphan and melphalan as conditioning for autologous blood stem cell transplantation in multiple myeloma. A feasibility study", Bone Marrow Transplant. 26, 1045-1049.
15. Corsini, C., Ghielmini, M., Mancuso, P., et al. (2000) "Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin", Br. J. Cancer 82, 524-528.
16. Martinelli, G., Pastano, R., Alietti, A., et al. (2001) "High dose chemotherapy with idarubicin and melphalan and peripheral blood stem cell transplantation in patients with poor risk or relapsed high grade non Hodgkin lymphoma", Haematologica 86(Suppl. 10), 1-279, Abst P0128.
17. Durie, B.G. and Salmon, S. (1975) "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival", Cancer 36, 842-854.
18. Gore, M.E., Selby, P.J., Clark, P.I., et al. (1989) "Intensive treatment of multiple myeloma and criteria for complete response", Lancet 2, 879-882.
19. World Health Organization (1979) WHO Handbock for Reporting Results of Cancer Treatment (World Health Organization, Geneva), p. 38.
20. Mandelli, F., Petti, M.C., Ardia, A., et al. (1991) "A Randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non lymphoid leukemia", Eur. J. Cancer 27, 750-755.